Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Observational Follow-up of Tanezumab Subjects Undergoing Joint Replacement
NCT02674386Phase 3Completed
- Sponsor
- Pfizer
- Start
- Aug 2016
- Primary completion
- Jul 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 15
01
Overview
Phase 3, single-arm trial of tanezumab in osteoarthritis (OA), sponsored by Pfizer. Primary endpoints: Surgeon's Assessment of Procedural Difficulty at Day 1, Self-Administered Patient Satisfaction Scale at 24 weeks and 9 more. Started Aug 2016; status: completed.
02
Drugs
tanezumab
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT02674386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02674386.